Search
Research
Clinical outcomes and severity of laboratory-confirmed RSV compared with influenza, parainfluenza and human metapneumovirus in Australian children attending secondary careAcute lower respiratory infections (ALRIs) are a major contributor to the global infectious disease burden and a common cause of hospitalisation for children under 2 years. We compared clinical severity in children hospitalised with respiratory syncytial virus (RSV), parainfluenza virus (PIV), human metapneumovirus (hMPV) and influenza virus (IFV).
Research
Novel coenzyme Q6 genetic variant increases susceptibility to pneumococcal diseaseAcute lower respiratory tract infection (ALRI) remains a major worldwide cause of childhood mortality, compelling innovation in prevention and treatment. Children in Papua New Guinea (PNG) experience profound morbidity from ALRI caused by Streptococcus pneumoniae. As a result of evolutionary divergence, the human PNG population exhibits profound genetic variation and diversity. To address unmet health needs of children in PNG, we tested whether genetic variants increased ALRI morbidity.
Research
Who is at risk of a respiratory syncytial virus hospitalisation? A linked, population-based birth cohort analysis in children aged less than 5 yearsRespiratory syncytial virus (RSV) is a major cause of acute lower respiratory infections globally in children under five years. With the development of RSV prevention strategies, understanding risk factors and relation to age and population is useful for deciding the type of program implemented.
Research
B Part of It School Leaver protocol: an observational study to assess the impact of a meningococcal serogroup B vaccine programme on carriage of Neisseria meningitidisThis study will assess the impact of MenB vaccine (4CMenB) on carriage prevalence in school leavers in South Australia
Research
Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series AnalysisPalivizumab appeared effective for reducing virologically confirmed respiratory syncytial virus in this high-risk cohort
Research
S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccineBased on descriptive analyses of this small study, S. aureus 3-antigen vaccine vaccination did not impact S. aureus acquisition or carriage
Research
The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of MethodologyOur review highlights similarities and differences in the application of the test-negative design that deserve further examination
Research
Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with Pneumococcal Conjugate VaccinePPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses
Research
Safety, tolerability, and effect of a single aural dose of Dornase alfa at the time of ventilation tube surgery for otitis media: A Phase 1b double randomized control trialOne third of children require repeat ventilation tube insertion (VTI) for otitis media. Disease recurrence is associated with persistent middle ear bacterial biofilms. With demonstration that Dornase alfa (a DNase) disrupts middle ear effusion biofilms ex vivo, we identified potential for this as an anti-biofilm therapy to prevent repeat VTI. First, safety and tolerability needed to be measured.
Research
Impact of ventilation tube insertion on long-term language outcomes at 6 and 10 years of age: A prospective pregnancy cohort studyInvestigating the impact of early childhood ventilation tube insertion (VTI) on long-term language outcomes.